	ORM 4]		OMB APPROVAL					
Form 4 or Form 5 o Instruction 1(b). Check this box to in made pursuant to a plan for the purchas the issuer that is into	longer subject to Section 16. bligations may continue. See dicate that a transaction was contract, instruction or written e or sale of equity securities of ended to satisfy the affirmative of Rule 10b5-1(c). See	Filed pursuant t	UNITED STATES SECURITIES AND EXCHANGE COMM Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF o Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of th	SECURITIES	OMB Number: Estimated average burden hours response	3235-0 per			
(Print or Type Responses) 1. Name and Address of Reporting Person * Chen Lichtenstein			2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited [TEVA]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) C/O Teva Pharmaceutical 124 Dvora HaNevi'a St.,	(First) Industries Ltd.	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 12/02/2025	Officer (give title below		w)			
(Street) Tel Aviv, L3 6944020			4. If Amendment, Date Original Filed (Month/Day/Year)	_ X _ Form filed by One Report	6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person _ Form filed by More than One Reporting Person				
(City)	(State)	(Zip)]						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

	1.Title of Security (Instr. 3)	Date (Month	Execution	Code		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Beneficial
				Code	V	Amount	(A) or (D)	Price			Ownership (Instr. 4)
ĺ	Ordinary Shares (1)	12/02/2025		M		4,804	A	(2)	4,804	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)		3. Transaction Date (Month /Day/Year)	Execution	4. Transaction Code (Instr. 8)		Derivative Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		(Instr. 5)	of Derivative	Ownership Form of Derivative	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Following Reported	Direct (D) or Indirect (I) (Instr. 4)	
Restricted Share Units	(2)	12/02/2025		М			4,804	(3)	(3)	Ordinary Shares ⁽¹⁾	4,804	\$ 0	0	D	

Explanation of Responses:

- 1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- 2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- 3. Restricted share units were granted on December 2, 2024 and vested on December 2, 2025.



Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.